Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer.

Conti RM, Dusetzina SB, Herbert AC, Berndt ER, Huskamp HA, Keating NL.

Med Care. 2013 Jul;51(7):622-7. doi: 10.1097/MLR.0b013e318290216f.

2.

How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab.

Dusetzina SB, Ellis S, Freedman RA, Conti RM, Winn AN, Chambers JD, Alexander GC, Huskamp HA, Keating NL.

J Oncol Pract. 2015 Jul;11(4):313-8. doi: 10.1200/JOP.2015.004218.

3.

Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy.

Fu AZ, Tsai HT, Marshall JL, Freedman AN, Potosky AL.

J Oncol Pharm Pract. 2014 Oct;20(5):332-40. doi: 10.1177/1078155213507010.

4.

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.

Wagner AD, Thomssen C, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008941. doi: 10.1002/14651858.CD008941.pub2. Review.

PMID:
22786517
5.

Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.

Parthan A, Santos E, Becker L, Small A, Lalla D, Brammer M, Teitelbaum A.

J Manag Care Spec Pharm. 2014 May;20(5):485-93.

6.

Bevacizumab for advanced breast cancer: hope, hype, and hundreds of headlines.

Fralick M, Ray M, Fung C, Booth CM, Mallick R, Clemons MJ.

Oncologist. 2013;18(11):1174-9. doi: 10.1634/theoncologist.2013-0160.

7.

Bevacizumab in the treatment of metastatic breast cancer: friend or foe?

Montero AJ, Escobar M, Lopes G, Glück S, Vogel C.

Curr Oncol Rep. 2012 Feb;14(1):1-11. doi: 10.1007/s11912-011-0202-z. Review.

8.

The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy.

Dawood S, Shaikh AJ, Buchholz TA, Cortes J, Cristofanilli M, Gupta S, Gonzalez-Angulo AM.

Cancer. 2012 Jun 1;118(11):2780-6. doi: 10.1002/cncr.26579.

9.

FDA cancels approval for bevacizumab in advanced breast cancer.

Tanne JH.

BMJ. 2011 Nov 25;343:d7684. doi: 10.1136/bmj.d7684. No abstract available.

PMID:
22121166
10.

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Shih T, Lindley C.

Clin Ther. 2006 Nov;28(11):1779-802. Review.

PMID:
17212999
11.

Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.

Preusser M, Fülöp G, Berghoff AS, Heinzl H, Steger GG, Greil R, Zielinski CC, Bartsch R.

Oncologist. 2012;17(7):e13-7. doi: 10.1634/theoncologist.2012-0115.

12.

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.

Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, Ciruelos E, von Moos R, Chang HT, Duenne AA, Miles DW.

Eur J Cancer. 2011 Nov;47(16):2387-95. doi: 10.1016/j.ejca.2011.06.018.

PMID:
21757334
13.

Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.

Clavarezza M, Turazza M, Aitini E, Saracchini S, Garrone O, Durando A, De Placido S, Bisagni G, Levaggi A, Bighin C, Restuccia E, Scalamogna R, Galli A, Del Mastro L.

Breast. 2013 Aug;22(4):470-5. doi: 10.1016/j.breast.2013.03.012.

PMID:
23642526
14.

[Application of bevacizumab on metastatic breast cancer].

Guo Yt, Ding L, Li Th.

Beijing Da Xue Xue Bao. 2012 Oct 18;44(5):708-14. Review. Chinese.

15.

Effect of Regulatory Requirement for Patient-Specific Prescriptions for Off-Label Medications on the Use of Intravitreal Bevacizumab.

Holfinger S, Miller AG, Rao LJ, Rowland DY, Hornik JH, Miller DG.

JAMA Ophthalmol. 2016 Jan;134(1):45-8. doi: 10.1001/jamaophthalmol.2015.4331.

PMID:
26540671
16.

Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.

Lynch TJ Jr, Spigel DR, Brahmer J, Fischbach N, Garst J, Jahanzeb M, Kumar P, Vidaver RM, Wozniak AJ, Fish S, Flick ED, Leon L, Hazard SJ, Kosty MP; ARIES Study Investigators..

J Thorac Oncol. 2014 Sep;9(9):1332-9. doi: 10.1097/JTO.0000000000000257.

17.

The life, death, and attempted rebirth of bevacizumab in breast cancer.

Seddon AN, Cuellar S, Haaf CM.

J Oncol Pharm Pract. 2014 Dec;20(6):433-44. doi: 10.1177/1078155213510193. Review.

PMID:
24200986
18.

Is the battle over bevacizumab coverage looming?

Larkin C.

J Natl Compr Canc Netw. 2011 Mar;9(3):261-3. No abstract available.

PMID:
21393437
19.

FDA pulls approval for avastin in breast cancer.

Rose S.

Cancer Discov. 2011 Dec;1(7):OF1-2. doi: 10.1158/2159-8290.CD-ND112311OL-08.

20.

Why have UK doctors been deterred from prescribing Avastin?

Cohen D.

BMJ. 2015 Apr 1;350:h1654. doi: 10.1136/bmj.h1654. No abstract available.

PMID:
25834024
Items per page

Supplemental Content

Support Center